Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction: Chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome

Cancer

Volumn 97, Issue 2, 2003, Pages 450-456

  Mattiuzzi, Gloria N ^a   Estey, Elihu ^a   Raad, Issam ^a   Giles, Francis ^a   Cortes, Jorge ^a   Shen, Yu ^a   Kontoyiannis, Dimitrios ^a   Koller, Charles ^a   Munsell, Mark ^a   Beran, Miloslav ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute leukemia; Fungal infection; Myelodysplastic syndrome; Prophylaxis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BILIRUBIN; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; FLUCONAZOLE; ITRACONAZOLE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BACKACHE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DYSPNEA; FEMALE; GASTRITIS; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037439347     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11094     Document Type: Article

References (22)

1. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545-1552.
2. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845-851.
3. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis. 1999;28:250-255.
4. Morgenstern GR, Prentice AG, Prentice HG, et al. A randomised controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol. 1999;105:901-911.
5. Ellis ME, Clink H, Ernst P, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis. 1994;13:3-11.
6. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med. 1993;118:495-503.
7. Bodey GP, Anaissie EJ, Elting L, Estey E, O'Brien S, Kantarkian H. Antifungal prophylaxis during remission induction therapy for acute leukemia. Fluconazole versus intravenous amphotericin B. Cancer. 1994;73:2099-2106.
8. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis. 1999;28:331-340.
9. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis. 1995;172:1035-1041.
10. Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann Intern Med. 1994;120:913-918.
11. Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. Cancer. 2000;89:1611-1612.
12. Rex JH, Walsh TJ, Anaissie EA. Fungal infections in iatrogenically compromised hosts. Adv Intern Med. 1998;43:321-371.
13. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
14. Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (ambisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant. 1999;23:163-168.
15. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 1993;12:577-582.
16. Glasmacher A, Molitor E, Hahn C, et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia. 1998;12:1338-1343.
17. Huijgens PC, Simoons-Smit AM, van Loenen AC, et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol. 1999;52:376-380.
18. Anderlini P, Luna M, Kantarjian HM, et al. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 1996;10:600-608.
19. Estey E, Keating M, McCredie K, Bodey G, Freireich E. Causes of initial remission failure in acute myelogenous leukemia. Blood. 1982;60:309-315.
20. Walsh TJ, Yeldandi V, McEvoy M, et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother. 1998;42:2391-2398.
21. Estey E, Thall PF, Kantarjian H, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood. 1992;79:2246-2255.
22. Estey E, Smith TL, Keating MJ, McCredie KB, Gehan EA, Freireich EJ. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia. 1989;3:257-263.